BIOCON Stock Overview
A biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 4/6 |
Past Performance | 3/6 |
Financial Health | 0/6 |
Dividends | 2/6 |
Biocon Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₹334.80 |
52 Week High | ₹349.45 |
52 Week Low | ₹217.50 |
Beta | 0.39 |
1 Month Change | 7.34% |
3 Month Change | 33.04% |
1 Year Change | 36.71% |
3 Year Change | -16.08% |
5 Year Change | 34.16% |
Change since IPO | 730.00% |
Recent News & Updates
Is Biocon (NSE:BIOCON) A Risky Investment?
Jun 11Biocon (NSE:BIOCON) Is Reducing Its Dividend To ₹0.50
Jun 11Biocon's (NSE:BIOCON) Promising Earnings May Rest On Soft Foundations
May 24Biocon's (NSE:BIOCON) Dividend Is Being Reduced To ₹0.50
May 23Recent updates
Is Biocon (NSE:BIOCON) A Risky Investment?
Jun 11Biocon (NSE:BIOCON) Is Reducing Its Dividend To ₹0.50
Jun 11Biocon's (NSE:BIOCON) Promising Earnings May Rest On Soft Foundations
May 24Biocon's (NSE:BIOCON) Dividend Is Being Reduced To ₹0.50
May 23Is Now The Time To Put Biocon (NSE:BIOCON) On Your Watchlist?
Mar 20Biocon Limited Just Beat EPS By 240%: Here's What Analysts Think Will Happen Next
Feb 12Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 18% Below Its Share Price
Jan 23Shareholders Should Be Pleased With Biocon Limited's (NSE:BIOCON) Price
Jan 03These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively
Nov 13Estimating The Intrinsic Value Of Biocon Limited (NSE:BIOCON)
Aug 03Biocon (NSE:BIOCON) Will Pay A Larger Dividend Than Last Year At ₹1.50
Jul 03Is Biocon (NSE:BIOCON) Using Too Much Debt?
Jul 02Biocon's (NSE:BIOCON) Dividend Will Be Increased To ₹1.50
May 26Estimating The Fair Value Of Biocon Limited (NSE:BIOCON)
Mar 28Here's Why Biocon (NSE:BIOCON) Can Manage Its Debt Responsibly
Feb 26Biocon Limited (NSE:BIOCON) Shares Could Be 24% Above Their Intrinsic Value Estimate
Dec 17Is There An Opportunity With Biocon Limited's (NSE:BIOCON) 46% Undervaluation?
Sep 05Is Biocon (NSE:BIOCON) Using Too Much Debt?
Jul 13Biocon Limited (NSE:BIOCON) Shares Could Be 20% Below Their Intrinsic Value Estimate
May 26Is Biocon (NSE:BIOCON) Using Too Much Debt?
Mar 28Biocon (NSE:BIOCON) Seems To Use Debt Quite Sensibly
Dec 27Shareholder Returns
BIOCON | IN Biotechs | IN Market | |
---|---|---|---|
7D | -0.4% | -0.1% | 2.7% |
1Y | 36.7% | 34.8% | 44.9% |
Return vs Industry: BIOCON matched the Indian Biotechs industry which returned 36.8% over the past year.
Return vs Market: BIOCON underperformed the Indian Market which returned 44.7% over the past year.
Price Volatility
BIOCON volatility | |
---|---|
BIOCON Average Weekly Movement | 5.7% |
Biotechs Industry Average Movement | 5.6% |
Market Average Movement | 6.5% |
10% most volatile stocks in IN Market | 9.4% |
10% least volatile stocks in IN Market | 4.3% |
Stable Share Price: BIOCON's share price has been volatile over the past 3 months.
Volatility Over Time: BIOCON's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1978 | 16,545 | Siddharth Mittal | www.biocon.com |
Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products. The company operates through Generics, Novel Biologics, Biosimilars, and Research Services segments. It focuses in the areas of diabetes, oncology, immunology, ophthalmology, and bone health diseases.
Biocon Limited Fundamentals Summary
BIOCON fundamental statistics | |
---|---|
Market cap | ₹399.75b |
Earnings (TTM) | ₹10.23b |
Revenue (TTM) | ₹147.56b |
39.1x
P/E Ratio2.7x
P/S RatioIs BIOCON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BIOCON income statement (TTM) | |
---|---|
Revenue | ₹147.56b |
Cost of Revenue | ₹48.98b |
Gross Profit | ₹98.58b |
Other Expenses | ₹88.35b |
Earnings | ₹10.23b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 8.56 |
Gross Margin | 66.81% |
Net Profit Margin | 6.93% |
Debt/Equity Ratio | 62.2% |
How did BIOCON perform over the long term?
See historical performance and comparisonDividends
0.1%
Current Dividend Yield6%
Payout RatioDoes BIOCON pay a reliable dividends?
See BIOCON dividend history and benchmarksBiocon dividend dates | |
---|---|
Ex Dividend Date | Jul 05 2024 |
Dividend Pay Date | Sep 06 2024 |
Days until Ex dividend | 19 days |
Days until Dividend pay date | 82 days |
Does BIOCON pay a reliable dividends?
See BIOCON dividend history and benchmarks